Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

3.5 hours. In seven out of 20 cases (35 percent), DP-PS correctly predicted the eventual outcome. These results seem to indicate that PS derived from DP model showed better correlation with drug exposure and could predict patient outcome better than Ktrans.

In a separate analysis, the effects of ABT-869 on biomarkers of angiogenesis were evaluated. Correlations of dose and pharmacokinetics of ABT-869, with serum biomarkers, tumor DCE-MRI tracer kinetics, proteinuria and hypertension were assessed. Results appeared to indicate that ABT-869 induced dose-dependent changes in serum biomarkers are consistent with anti-angiogenic activity. However, these serum biomarkers had limited value in predicting safety, i.e., proteinuria or hypertension. The utility of tumor flow and permeability changes on DCE-MRI in predicting proteinuria should be further examined. Updated information will be presented at the ASCO Annual Meeting.

Background on Abbott's Oncology Pipeline

Bcl-2 Family Protein Inhibitors (ABT-263)

Researchers have been interested in the Bcl-2 family of proteins since their role in preventing apoptosis -- the natural process by which damaged or unwanted cells die and are cleared from the body -- was proven more than a decade ago. Discovered by Abbott scientists, ABT-263 restores programmed cell death, a natural mechanism for the elimination of cancerous cells, by inhibiting the function of Bcl-2 proteins.

Bcl-2 proteins play a central role in regulating apoptosis, as well as tumor formation, tumor growth and resistance to treatment. Pioneering work in structural biology at Abbott established how the Bcl-2 family proteins interact with one another, leading researchers to develop a novel compound that causes cancer cells to self-destruct.

ABT-263 is in Phase I/II clinical trials for lymphomas and solid tumors, including small cell lung cancer. Preclinical data has shown that Abbott's Bcl-2 family protein inhibitors bind to Bc
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... NY (PRWEB) September 21, 2014 The ... help businesses and manufacturers perform tests on items ranging ... an increasingly regulated society, pressure on operators to ensure ... than ever. A greater number of government safety regulations ... manufacturers' goods prior to sale. Although revenue briefly dipped ...
(Date:9/21/2014)... September 22, 2014 The asthma ... decade, as it has become saturated with relatively ... inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists ... facing increasing generic competition. However, the launch of ... and ICS/LABA therapies delivered by the next-generation inhalers ...
(Date:9/21/2014)... New York (PRWEB) September 21, 2014 ... continue to move forward in Pennsylvania’s Philadelphia Court ... to court documents, the proceeding’s next monthly meeting ... Litigation, case number 100300296) , “Our Firm is ... Risperdal lawsuits in this litigation. We are pleased ...
(Date:9/21/2014)... Discount-Dress.com, a company that ... announced its decision to implement a new shopping cart ... ladies across the world. Furthermore, the company has unveiled ... , The new items come in fashionable designs; ... up to 56 percent off. "We are happy to ...
(Date:9/21/2014)... Rio, Colorado (PRWEB) September 21, 2014 ... Colorado, ten teams of disabled and able-bodied athletes rafted ... and completed a ropes course in pursuit of outdoor ... from national non-profit World T.E.A.M. Sports, disabilities proved ... athletes who successfully completed the three stage event. , ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3
... smoke. According to a recent study researchers find smoking during ... having a baby with a cleft lip. ,The study, ... their babies were about six months old. Researchers asked about ... many cigarettes she smoked and whether she was exposed to ...
... of osteoarthritis the major cause of disability in ... a few weeks // say researchers according to ... in Europe and the United States recommend the ... to relieve osteoarthritis pain. ,Researchers explain many ...
... could be the first step in the path for a ... first time they have found a successful way to deliver ... mouse. ,Gene therapy for muscular dystrophy has been ... the whole body has been a major obstacle for scientists. ...
... drug for the treatment of alcohol dependence. But one of ... which can reduce medication compliance and can be absorbed // ... injection of naltrexone and the benefit of its use for ... they were randomly assigned to get an injection of naltrexone ...
... clinical trial of people infected with both HIV and hepatitis ... their study, patients who are treated with a newer combination ... of HCV than those who receive standard therapy. ,The ... estimated 1 million Americans infected with HIV also have HCV, ...
... low-fat salad dressing anymore. New research shows fats actually ... ,Researchers studied men and women between ages 19 ... with salad dressing that contained zero, six or 28 ... 11 hours following each meal. ,Results showed that ...
Cached Medicine News:
(Date:9/19/2014)... Sept. 19, 2014 Today, iHealth Lab Inc. announced ... Ventures, Ltd. for its first institutional round of funding. ... iHealth,s global reach, accelerate growth and innovation, and invest ... the investment, Xiaomi Ventures will join iHealth,s board of ... infrastructure and ecommerce. "We are very pleased ...
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... of Kent Hance , the former chancellor of Texas ... retired as chancellor in July 2014, after raising $1.2 billion ... that Kent Hance , the most successful chancellor in ... team not only as an investor, but also as our ...
(Date:9/19/2014)... 19, 2014  For Cloud Pharmaceuticals, Inc., a ... development, partnering is an integral part of its ... new drugs and identify early stage, preclinical, IND, ... their development. The company also partners with funds ... business model, Cloud Pharmaceuticals will be participating in ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... Calif., Jan. 27, 2011 AVANIR Pharmaceuticals, Inc. (Nasdaq: ... release unaudited financial results for the quarter ended December ... 2011.  Keith Katkin, President and Chief Executive Officer, Randall ... and Christine Ocampo, Vice President, Finance, will host an ...
... SAN DIEGO, Jan. 27, 2011 Profil™ Institute for ... early phase clinical trials for diabetes and obesity, announced ... speaker at the Ramanbhai Foundation 5th International Symposium and ... The Ramanbhai Foundation,s International Symposium will be ...
Cached Medicine Technology:Profil Institute's CEO Presenting on Early Phase Clinical Research in India 2Profil Institute's CEO Presenting on Early Phase Clinical Research in India 3
... LH Ovulation Predicting Test is a qualitative ... Hormone (hLH) in human urine to predict ... by the elevation of human luteinizing hormone ... period starts, hLH has a brief, significant ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... The Shandon Varistain 24-4 ... stainer designed to offer simplicity ... cytology staining applications. It is ... load and continuous throughput. ...
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: